mdl 11939 has been researched along with Schizophrenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristow, LJ; Hutson, PH; Rowley, M | 1 |
| Elizalde, DI; Gallitano, AL; González-Maeso, J; Ingram, WM; Janowski, SA; Kamel, CM; Kozlenkov, A; Levine, S; Lish, JR; Resnik, J; Shoker, J; Williams, AA | 1 |
1 review(s) available for mdl 11939 and Schizophrenia
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
1 other study(ies) available for mdl 11939 and Schizophrenia
| Article | Year |
|---|---|
Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.
Topics: Animals; Clozapine; Disease Models, Animal; Early Growth Response Protein 3; Humans; Hypnotics and Sedatives; Ketanserin; Male; Mice; Mice, Transgenic; Motor Activity; Piperidines; Receptor, Serotonin, 5-HT2A; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists | 2012 |